Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: Antigen-specific T cell responses in DTH skin tests

Annals of Oncology

Volumn 17, Issue 6, 2006, Pages 974-980

  Lesterhuis, W J ^a   de Vries, I J M ^a   Schuurhuis, D H ^a   Boullart, A C I ^a   Jacobs, J F M ^a   de Boer, A J ^a   Scharenborg, N M ^a   Brouwer, H M H ^a   van de Rakt, M W M M ^a   Figdor, C G ^a   Ruers, T J ^a   Adema, G J ^a   Punt, C J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer vaccine; Carcinoembryonic antigen; Colorectal cancer; Delayed type hypersensitivity reaction; Dendritic cells; Immunomonitoring

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; LOPERAMIDE;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DIARRHEA; DRUG EFFICACY; FLU LIKE SYNDROME; HUMAN; HUMAN TISSUE; INTERFERON PRODUCTION; INTERMETHOD COMPARISON; LIVER METASTASIS; LYMPH NODE BIOPSY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SKIN TEST; T LYMPHOCYTE; TARGET CELL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY;

ADULT; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DENDRITIC CELLS; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERSENSITIVITY, DELAYED; LIVER NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOCYTE ACTIVATION; MONITORING, IMMUNOLOGIC; PATIENT SELECTION; SKIN TESTS; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33646863192     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl072     Document Type: Article

References (32)

1. Punt CJ. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 2004; 15: 1453-1459.
2. de Kleijn EM, Punt CJ. Biological therapy of colorectal cancer. Eur J Cancer 2002; 38: 1016-1022.
3. Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol 2005; 16: 847-862.
4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
5. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: Mapping the way. Nat Med 2004; 10: 475-480.
6. Lesterhuis WJ, de Vries IJ, Adema GJ, Punt CJ. Dendritic cell-based vaccines in cancer immunotherapy: An update on clinical and immunological results. Ann Oncol 2004; 15 (Suppl 4): Iv145-151.
7. Morse MA, Deng Y, Coleman D et al. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999; 5: 1331-1338.
8. Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001; 98: 8809-8814.
9. Matsuda K, Tsunoda T, Tanaka H et al. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother 2004; 53: 609-616.
10. Itoh T, Ueda Y, Kawashima I et al. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother 2002; 51: 99-106.
11. Liu KJ, Wang CC, Chen LT et al. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 2004; 10: 2645-2651.
12. Morse MA, Clay TM, Hobeika AC et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 2005; 11: 3017-3024.
13. Morse MA, Clay TM, Lyerly HK. CEA loaded dendritic cell vaccines. Cancer Chemother Biol Response Modif 2002; 20: 385-390.
14. Dhodapkar MV, Krasovsky J, Steinman RM, Bhardwaj N. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest 2000; 105: R9-R14.
15. de Vries IJ, Lesterhuis WJ, Scharenborg NM et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003; 9: 5091-5100.
16. Jonuleit H, Giesecke-Tuettenberg A, Tuting T et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001; 93: 243-251.
17. Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003; 21: 4016-4026.
18. Hallmeyer S, Perambakam S, Reddy S et al. A randomized trial of PSA-peptide based specific active immunotherapy in HLA-A2+ patients with prostate cancer: Comparison of two different vaccination strategies. J Clin Oncol 2005; 23 (Suppl): Abstr 2519.
19. de Vries IJ, Bernsen MR, Lesterhuis WJ et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005; 23: 5779-5787.
20. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: A review. J Clin Oncol 2002; 20: 2197-2207.
21. Jonuleit H, Kuhn U, Muller G et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 3135-3142.
22. de Vries IJ, Eggert AA, Scharenborg NM et al. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 2002; 25: 429-438.
23. Tsang KY, Zaremba S, Nieroda CA et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87: 982-990.
24. Jaeck D. The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies. Ann Surg Oncol 2003; 10: 1007-1011.
25. Nagorsen D, Keilholz U, Rivoltini L et al. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/ neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res 2000; 60: 4850-4854.
26. Vissers JL, Hartgers FC, Lindhout E et al. Quantitative analysis of chemokine expression by dendritic cell subsets in vitro and in vivo. J Leukoc Biol 2001; 69: 785-793.
27. Martin-Fontecha A, Sebastiani S, Hopken UE et al. Regulation of dendritic cell migration to the draining lymph node: Impact on T lymphocyte traffic and priming. J Exp Med 2003; 198: 615-621.
28. Coulie PG, Karanikas V, Colau D et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 2001; 98: 10290-10295.
29. Lonchay C, van der Bruggen P, Connerotte T et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 2004; 101 (Suppl 2): 14631-14638.
30. Lurquin C, Lethe B, De Plaen E et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005; 201: 249-257.
31. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274.
32. Romero P, Dunbar PR, Valmori D et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998; 188: 1641-1650.